Alembic Pharmaceuticals Limited reported its consolidated financial results for the period ending 31 March 2021.
Financial Highlights for the Quarter
• Net Sales for the quarter up 6% to Rs 1280 crores.
• Net Profit for the quarter up 12% to Rs 251 crores from Rs 225 crores.
Financial Highlights for the Year
• Net sales for FY21 up 17% to Rs 5393 crores against Rs 4606 crores.
• Net profit for FY21 up 42% to Rs 1178 crores from Rs 829 crores.
Operational Highlights
International Business
• International formulations grew 19% to Rs 2942 crores for FY21.
• US Generics grew 9% to Rs 2163 crores for FY21
• Ex-US International Formulations grew 57% to Rs 779 Crores for FY21.
• 13 ANDA’s were filed in the quarter and 29 ANDA filings for the year.
• R&D spend at 12% of revenue or Rs 670 Crores for the year.
India Branded Formulations Business
• India branded formulations business grew 5% to Rs 1497 crores for FY21
API Business
• API business grew 38% to Rs 214 crores in the quarter and 35% to Rs 955 crores for FY21.
• 2 DMF were filed in the quarter, Cumulative DMF fillings at 117.
